Sodium Divalproate in Low Alternating Daily Doses for Migraine Prevention: A Retrospective Study

The retrospective study evaluated the use of sodium divalproate (SD) in low alternating daily doses for migraine prevention in 68 patients from a tertiary center. The study found that the average headache frequency decreased from 8.2 to 5.1 days per month after 2 months, with an adherence rate of 73.5%, and further reduced to 4.2 days per month at 4 months, with an adherence rate of 61.8%. However, weight gain was a side effect, reported by 30% of patients at 2 months and 42.8% at 4 months. Despite the study's limitations, such as its retrospective design, the findings suggested that low alternating doses of SD might be effective, though controlled studies were needed for confirmation.